Skip to main content

Malignancy marker for therapy planning

Ref-Nr: TA-5158


Kurzfassung

Early classification of aggressive prostate cancers


Hintergrund

The diagnosis, classification and therapy of prostate cancer are based on the PSA value, the Gleason score from histology obtained by prostate biopsies and an imaging diagnosis from CT and bone scintigraphy. The variability of prostate cancer ranges from low-risk tumors without progression over many years to high-risk tumors with rapid local progression and high metastasis potential. There is a correlation with the risk for metastasis and the Gleason score, however there is an ongoing search for new biomarkers that directly correlate with the risk for metastasis.


Bilder & Videos


Lösung

Vimentin 3 (Vim3) has been discovered as biomarker, which correlates with the risk of progression of prostate cancer. Results show high expression of Vim3 in cells of metastatic prostate and low expression in non-metastatic cancer, thus demonstrating the potential of Vim3 for risk stratification of localized prostate carcioma to enable personalized therapy planning.

Vim3 is a truncated and biologically active variant of Vimentin. Healthy cells express the Vimentin full-length variant (Vim-fl) and are characterized by a functional cytoskeleton. If Vim-fl is no longer expressed in the cells, Vim3 is predominantly detectable. In this case the intracellular structure of the cell is disordered due to the loss of the normal cytoskeletal architecture with the consequence that cells become deformable and consequently mobile.

To date, 200 serum samples from prostate cancer patients, resectates and biopsies have been examined. A validation on about 800 serum samples is planned. Data on additional tumor types are available, including urethel cancer and breast cancer.


Vorteile

  • early classification of aggressive prostate cancers for personalized therapy planning
  • applicable for analyzing tissue samples and liquid biopsies
  • also relevant for other tumor entities (e.g. esophagus, breast cancer)
  • additional biomarker that can be measured in an easy and objective way

Anwendungsbereiche

Prostate cancer is the second most common cancer in males. An estimated 1.1 million men worldwide were diagnosed with prostate cancer in 2012, accounting for 15% of the cancers diagnosed in males. The selection of the therapeutic strategy depends on the risk classification. There is a strong medical need to precisely identify those patients whose disease allows monitoring without therapeutic intervention, in order to avoid overtreatment, which comes along with high medical costs and loss of life quality.


PROvendis GmbH

Dipl.-Biol. Kordula Kruber
+49.208 94105-30
kk@provendis.info
www.provendis.info
Adresse
Schloßstr. 11-15
45468 Mülheim an der Ruhr



Entwicklungsstand

Klinischer Funktionsnachweis


Patentsituation

  • EP anhängig

Stichworte

Prostata, Prostatakarzinom, Urothel-Krebs, Harnblasenkarzinom, Harnleiterkarzinom, Biomarker, Tumormarker, Vimentin 3, Vimentin, Risikostratifiierung/Risikostratifikation, Metastase, Metastasierung, personalisierte Therapieplanung, Therapieplanung, Prostate, prostate cancer, urothelial cancer, bladder cancer, urethel cancer, biomarker, tumormarker, vimentin 3, Vimentin, risk stratification, patient selection/classification, metastasis, personalized therapy, therapeutic strategy

Angebot Anbieter-Website


Kontakt | Geschäftsstelle

TechnologieAllianz e. V.
Christiane Bach-Kaienburg
(Geschäftsstellenleiterin)

c/o PROvendis GmbH
Schloßstr. 11-15
D-45468 Mülheim an der Ruhr